Advances in venom peptide drug discovery: where are we at and where are we heading?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Introduction: Animal venoms are a complex mixture of bioactive molecules that have evolved over millions of years for prey capture and defense from predators. Venom consists of many different types of molecules, with disulfide-rich peptides being a major component in most venoms. The study of these potent and highly selective molecules has led to the development of venom-derived drugs for diseases such as type 2 diabetes mellitus and chronic pain. As technologies have improved, more bioactive peptides have been discovered from venomous animals. Many of these molecules may have applications as tools for understanding normal and disease physiology, therapeutics, cosmetics or in agriculture.Areas covered: This article reviews venom-derived drugs approved by the FDA and venom-derived peptides currently in development. It discusses the challenges faced by venom-derived peptide drugs during drug development and the future for venom-derived peptides.Expert opinion: New techniques such as toxin driven discovery are expanding the pipeline of venom-derived peptides. There are many venom-derived peptides currently in preclinical and clinical trials that would have remained undiscovered using traditional approaches. A renewed focus on venoms, with advances in technology, will broaden the diversity of venom-derived peptide therapeutics and expand our knowledge of their molecular targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669 · cited 1×
“These include increasing plasma protein binding, covalent linkage to albumin-binding small molecules or conjugation to large polymers such as polyethylene glycol (PEG) groups [99].”
BackgroundDifferentiation and death of premyelinating oligodendrocytes in developing rodent brain
Trapp, B. D., Nishiyama, A., Cheng, D., & Macklin, W. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.137.2.459 · Cited by 395
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent
Furman, B. L. (2012) · Toxicon · doi:10.1016/j.toxicon.2010.12.016 · Cited by 166 · cited 1×
“Exenatide (Byetta®) Peptide GLP-1 receptor agonist Heloderma suspectum (lizard) T2DM Amylin Pharmaceuticals 2005 [22]”
BackgroundCornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156 · cited 1×
“Exenatide (Byetta®) derived from the venom of the Gila monster, Heloderma suspectum, is used for the treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control [9].”
MethodExenatide once weekly for the treatment of type 2 diabetes
Malone, J., Trautmann, M., Wilhelm, K., Taylor, K., & Kendall, D. M. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780902766802 · Cited by 55 · cited 1×
“This extends the duration of exenatide release, allowing for the therapeutic levels of the drug to be maintained with weekly injections [11].”
Background
Cited by
Cobra Venom: From Envenomation Syndromes to Therapeutic Innovations
Lafnoune, A., Chbel, A., Darkaoui, B., Nait Irahal, I., & Oukkache, N. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10646-2 · Cited by 9
New perspective for pathomechanism and clinical applications of animal toxins: Programmed cell death
Sun, J., Liu, J., Liu, M., Bi, X., & Huang, C. (2024) · Toxicon · doi:10.1016/j.toxicon.2024.108071 · Cited by 6
Molecular Display of the Animal Meta-Venome for Discovery of Novel Therapeutic Peptides
Hsiao, M.-H., Miao, Y., Liu, Z., Schütze, K., Limjunyawong, N., Chien, D. C.-C., Monteiro, W. D., Chu, L.-S., Morgenlander, W., Jayaraman, S., et al. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100901 · Cited by 5
Metadata
- Authors
- Smallwood, T. B., & Clark, R. J.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2021-05-24
- Volume
- 16
- Issue
- 10
- Pages
- 1163-1173
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W3157208633
- Cited by
- 48
- References
- 6
- FWCI
- 3.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advances in venom peptide drug discovery: where are we at and where are we heading? https://app.cochat.ai/papers/10.1080/17460441.2021.1922386
- The paper
- Smallwood, T. B., & Clark, R. J. (2021). Advances in venom peptide drug discovery: where are we at and where are we heading? Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2021.1922386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.